摘要
目的 :探讨NF -κB和AP - 1在哮喘发病中的作用和临床意义。方法 :用免疫组化方法检测了 2 3例哮喘患儿组、10例哮喘患儿临床控制组和 10例正常对照组痰液炎性细胞中NF -κB和AP - 1的表达。结果 :各组哮喘患儿和正常对照儿童痰液中NF -κB和AP - 1表达仅见于淋巴细胞 ,但在中性粒细胞、嗜酸细胞和巨噬细胞均未见二者的表达。病情缓解期哮喘患儿与急性发作期和正常对照组相比痰液中表达NF -κB和AP - 1阳性淋巴细胞数明显增加 ,并与病情成正相关。治疗后 3个月与病情缓解期相比NF -κB和AP - 1阳性淋巴细胞数有下降趋势 ,至治疗后 6个月和 9个月时有明显下降。哮喘患儿病情缓解至治疗后 6个月时NF -κB和AP - 1阳性淋巴细胞数持续升高 ,但在治疗后 9个月及临床控制组与正常对照组相比无明显差别。结论 :活化的NF -κB和AP - 1可能通过增加淋巴细胞炎性蛋白的合成参与了哮喘的慢性气道炎症。痰液中表达NF -κB的阳性淋巴细胞数可以反映哮喘患儿的病情及气道炎症的状况 。
Objective:To explore the role of NF-κB and AP-1 in the pathogenesis of asthma and clinical significance. Method:We examined the expression of NF-κB and AP-1 in inflammatory cells of sputum from 23 asthmatic children、10 clinically controlled asthmatic children and 10 normal control children with immunohistochemical methods. Result: Positive expression of NF-κB and AP-1 was found in lymphycytes of sputums in all groups ,but not found in neutrophills、eosinophills and macrophages.Compared with acute excerbation stage and normal control group,the positive lymphocyte numbers of expressed NF-κB and AP-1 in the sputums of remission stage significantly increased,and were positively related to disease severity.Compared with remission stage, the positive lymphocyte numbers of expressed NF-κB and AP-1 in the sputums of three months after treatment had a tendency to decline ,but significantly declined until six and nine months after treatment. The positive lymphocyte numbers of expressed NF-κB and AP-1 in the sputums from remission stage to six months after treatment persistently increased. There was no significant difference between nine months group after treatment and clinically controlled group and normal control group. Conclusion:Activated NF-κB and AP-1 involve in chronic airway inflammatory in asthma probablly by increasing the synthesis of inflammatory proteins of lymphocytes.The positive lymphocyte numbers of expressed NF-κB in the sputums may reflect the disease severity of asthmatic children and degrees of airway inflammation in asthma,So it can become a marker to evaluate airway inflammation in asthma.
出处
《河北医学》
CAS
2003年第7期584-587,共4页
Hebei Medicine